Video Journal of Oncology (VJOncology)

NEW #podcast episode: 'Updates in #immunotherapy for #skincancer’ 🎧 In this episode we cover: 🔦 Impact of T-Cell therapies, such as #lifileucel, in patients with #melanoma 🔦 Results of the 7-year CheckMate 238 trial (NCT02388906) of #nivolumab 🔦 Effective #sequencing of treatments in the #SECOMBITtrial (NCT02631447) 🔦 Challenges in managing immunotherapy related #adverseevents With leading experts:  🌟 Omid Hamid, MD, The Angeles Clinic & Research Institute, Inc. 🌟 Paolo A. Ascierto, MD, IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy 🌟 Georgina Long, PhD, MBBS, FRACP, FAHMS, Medicine and Health - University of Sydney 🌟 Karijn Suijkerbuijk, MD, PhD, UMC Utrecht Give it a listen 👉https://lnkd.in/eqnYMHRa Use the time codes to skip to your favourite part of each episode 👀 SUBSCRIBE so you don't miss any future episodes📱 #VJOncology

Happy Holidays from VJOncology! 🎄☃️ 🧣 As 2024 comes to an end, we want to thank all of you—our incredible audience, expert contributors, and supporters—for being part of our journey this year 💙 Wishing you a joyful holiday season and a happy, healthy New Year ✨ Here’s to an even bigger and better 2025! 🌟 #VJOncology #HappyHolidays

What an incredible year it's been 💙 ✨ As 2024 comes to an end, we want to say a big thank you to our incredible audience and everyone who supports VJOncology.com - we couldn’t have done this without you 👏 We are especially grateful for all the world-leading #Oncology experts who speak with us and those who provide editorial advice to help shape the content of our journals, allowing us to bring you relevant, cutting-edge and high quality scientific information 🧪 🎥🗞️ Here's to an even better 2025 ✨ Check out the latest congress coverage from #SABCS, #SITC, #ESMO & more 👉 https://lnkd.in/eTMErxb6 Or catch up on the latest in a disease area of your choice through our Disease Channels 👉 https://lnkd.in/eKyYWN5A #BCsm #LCsm #GUsm #GIsm #PCsm #CRCsm #Oncologynews #VJOncology

At #SABCS24 I discussed with Video Journal of Oncology (VJOncology) the results of DECRESCENDO, our investigator-initiated clinical trial of chemotherapy de-escalation in HER2+ early breast cancer OncoAlert

Very nice to have been included here with some big hitters, does nothing for my imposter syndrome. With #LungCancer awareness month coming to a close it’s time to reflect on all the great work done globally to advance the field. But specifically the work done in the UK is significant in my view. Having just returned home from the Cruk Lung Cancer Centre of Excellence meeting I am reflecting on all the great work done there and at other institutions around the country. Lots of progress, but we still need more basic research, more discovery, more trials and all with the same level of compassion for our patients, our colleagues and ourselves.

The NeoMono trial #SABCS24 Report with Hans-Christian Kolberg https://buff.ly/3BBzAjU Phase II neoadjuvant study in triple-negative #BreastCancer patients, explored the role of PD-L1 as a biomarker for immune checkpoint inhibitor therapy. Despite the trial’s unique design and high rates of pathologic complete response (PCR), especially among PD-L1 positive patients, no significant treatment interaction was observed. PD-L1 continues to show strong potential as an important biomarker for identifying patients who may benefit from immunotherapy, reinforcing its relevance in guiding treatment decisions. ( Video Journal of Oncology (VJOncology) )

NEW from #SABCS2024 | DECRESCENDO: de-escalating #chemotherapy in #HER+, #HR- early #breastcancer 🎥 🇺🇸 Elisa Agostinetto, MD, Institut Jules Bordet, discusses findings from the Phase II DECRESCENDO trial (NCT04675827) of #anthracycline-free treatment for #HER2-positive, #HR-negative, node-negative early #breastcancer Patients received #neoadjuvant #taxane-based therapy with #pertuzumab and #trastuzumab, achieving a high pathologic complete response. Although terminated early due to slow recruitment, the study demonstrates the potential of de-escalated regimens to maintain efficacy while minimizing long-term chemotherapy-related toxicity 🌟 Learn more 👉 https://lnkd.in/e7sgtuWE #VJOncology #Oncologynews

NEW #podcast episode: '#Antibody drug conjugates in #gastrointestinalcancers’ 🎧 We are joined by: 🌟 Kohei Shitara (National Cancer Center Hospital East) 🌟 Yelena Janjigian (Memorial Sloan Kettering Cancer Center) 🌟 John Strickler (Duke Cancer Institute) 🌟 Scott Kopetz (MD Anderson Cancer Center) Highlights include novel treatment strategies in #HER2-expressing #gastriccancer, findings from the #DESTINY-Gastric03 and ABBV-400 trials, and the role of CEACAM5-targeting ADCs in #colorectalcancer Give it a listen 👉 https://lnkd.in/eJygWigg Use the time codes to skip to your favourite part of each episode 👀 SUBSCRIBE so you don't miss any future episodes📱 #VJOncology #Oncologynews #CRCsm

Prof. Dr. med. Hans-Christian Kolberg, MD, Marienhospital Bottrop discusses the NeoMono trial in #TNBC at #SABCS24 🇺🇸 🎥 🌟High PCR rates in PD-L1+ patients 🌟PD-L1 = key biomarker for #immune checkpoint therapy Take a look 👉 https://ow.ly/WgIu50Ur1Rj #BreastCancer #BCSM #ImmunoOnc #CTSM #TrialUpdates

From my interview with Video Journal of Oncology (VJOncology) in San Antonio Breast Cancer Symposium to discuss our study.